Compare Citius Pharmaceuticals Inc (CTXR) vs Firy Inc. (FIRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Firy Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Firy Inc. trades at $10.31 (market cap $159.51M). The key difference: Firy Inc. is far larger — about 8× Citius Pharmaceuticals Inc's market cap, and Firy Inc. is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | FIRY | |
|---|---|---|
Market Cap | $20.01M | $159.51M |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $12.45 |
52-Week Low | $0.48 | $2.28 |
Enterprise Value | $16.23M | $103.18M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.765, up 13.0% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong analyst support with 83% buy ratings but faces significant financial challenges including negative earnings, a -823.34% net income margin, and consecutive quarterly EPS misses. Recent news highlights expansion of LYMPHIR cancer treatment commercialization with 78% quarterly growth in new institutional accounts.
While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial losses and negative cash flow from operations present significant investment risks. The company's ability to achieve profitability through its oncology drug commercialization will determine long-term shareholder value creation.
FIRY (formerly Skillz Inc.) trades at $9.98, down 4.77% today, with a bullish technical signal from moving averages. The company shows persistent losses with a -67.38% net margin in 2025 despite an 87.75% gross margin, while revenue declined from $270M in 2022 to $104M in 2025. Recent developments include a legal victory securing $719M and a corporate rebranding to FIRY.
The outlook remains challenging due to sustained negative cash flows and profitability issues, though the legal win provides a potential catalyst. Analyst sentiment is mixed with 60% hold ratings. Key risks include execution on profitability and competitive pressures in mobile gaming.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
